203 related articles for article (PubMed ID: 21922751)
21. Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response.
de Brito CA; Goldoni AL; Sato MN
Immunotherapy; 2009 Sep; 1(5):883-95. PubMed ID: 20636030
[TBL] [Abstract][Full Text] [Related]
22. The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans.
Ferwerda G; Netea MG; Joosten LA; van der Meer JW; Romani L; Kullberg BJ
Vaccine; 2010 Jan; 28(3):614-22. PubMed ID: 19887129
[TBL] [Abstract][Full Text] [Related]
23. Structural requirements for uptake and recognition of CpG oligonucleotides.
Heeg K; Dalpke A; Peter M; Zimmermann S
Int J Med Microbiol; 2008 Jan; 298(1-2):33-8. PubMed ID: 17706458
[TBL] [Abstract][Full Text] [Related]
24. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
[TBL] [Abstract][Full Text] [Related]
25. Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities.
Chisholm D; Libet L; Hayashi T; Horner AA
J Allergy Clin Immunol; 2004 Mar; 113(3):448-54. PubMed ID: 15007346
[TBL] [Abstract][Full Text] [Related]
26. Antigen presentation and dendritic cell biology in malaria.
Stevenson MM; Urban BC
Parasite Immunol; 2006; 28(1-2):5-14. PubMed ID: 16438671
[TBL] [Abstract][Full Text] [Related]
27. The science of adjuvants.
Kwissa M; Kasturi SP; Pulendran B
Expert Rev Vaccines; 2007 Oct; 6(5):673-84. PubMed ID: 17931149
[TBL] [Abstract][Full Text] [Related]
28. Phosphatidylinositol mannosides are efficient mucosal adjuvants.
Parlane NA; Denis M; Severn WB; Skinner MA; Painter GF; La Flamme AC; Ainge GD; Larsen DS; Buddle BM
Immunol Invest; 2008; 37(2):129-42. PubMed ID: 18300038
[TBL] [Abstract][Full Text] [Related]
29. Achievement of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotype.
Hanyecz A; Berlo SE; Szántó S; Broeren CP; Mikecz K; Glant TT
Arthritis Rheum; 2004 May; 50(5):1665-76. PubMed ID: 15146438
[TBL] [Abstract][Full Text] [Related]
30. The control of adaptive immune responses by the innate immune system.
Schenten D; Medzhitov R
Adv Immunol; 2011; 109():87-124. PubMed ID: 21569913
[TBL] [Abstract][Full Text] [Related]
31. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants.
Petersen LK; Ramer-Tait AE; Broderick SR; Kong CS; Ulery BD; Rajan K; Wannemuehler MJ; Narasimhan B
Biomaterials; 2011 Oct; 32(28):6815-22. PubMed ID: 21703679
[TBL] [Abstract][Full Text] [Related]
32. CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle.
Kovacs-Nolan J; Mapletoft JW; Latimer L; Babiuk LA; Hurk Sv
Vaccine; 2009 Mar; 27(14):2048-54. PubMed ID: 19428829
[TBL] [Abstract][Full Text] [Related]
33. Principles of vaccine design-Lessons from nature.
Zepp F
Vaccine; 2010 Aug; 28 Suppl 3():C14-24. PubMed ID: 20713252
[TBL] [Abstract][Full Text] [Related]
34. Vaccine adjuvants: scientific challenges and strategic initiatives.
Harandi AM; Davies G; Olesen OF
Expert Rev Vaccines; 2009 Mar; 8(3):293-8. PubMed ID: 19249971
[TBL] [Abstract][Full Text] [Related]
35. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants.
Sokolovska A; Hem SL; HogenEsch H
Vaccine; 2007 Jun; 25(23):4575-85. PubMed ID: 17485153
[TBL] [Abstract][Full Text] [Related]
36. Use of CpG oligodeoxynucleotides as immune adjuvants.
Klinman DM; Currie D; Gursel I; Verthelyi D
Immunol Rev; 2004 Jun; 199():201-16. PubMed ID: 15233736
[TBL] [Abstract][Full Text] [Related]
37. Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity.
Prchal M; Pilz A; Simma O; Lingnau K; von Gabain A; Strobl B; Müller M; Decker T
Vaccine; 2009 Dec; 27 Suppl 6():G17-20. PubMed ID: 20006134
[TBL] [Abstract][Full Text] [Related]
38. Innate immune control of nucleic acid-based vaccine immunogenicity.
Koyama S; Coban C; Aoshi T; Horii T; Akira S; Ishii KJ
Expert Rev Vaccines; 2009 Aug; 8(8):1099-107. PubMed ID: 19627190
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response.
Edwards DK; Jasny E; Yoon H; Horscroft N; Schanen B; Geter T; Fotin-Mleczek M; Petsch B; Wittman V
J Transl Med; 2017 Jan; 15(1):1. PubMed ID: 28049494
[TBL] [Abstract][Full Text] [Related]
40. Skin delivery of a hybrid liposome/ISCOM vaccine implicates a role for adjuvants in rapid modulation of inflammatory cells involved in innate immunity before the enhancement of adaptive immune responses.
Chin J; San Gil F
Immunol Cell Biol; 1998 Jun; 76(3):245-55. PubMed ID: 9682968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
